Progress towards clinically useful aldosterone synthase inhibitors

Current Topics in Medicinal Chemistry

Volumn 13, Issue 12, 2013, Pages 1385-1401

  Cerny, Matthew A ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Aldosterone; Aldosterone synthase; Cortisol; Cortisol synthase; Cytochrome P450; Inhibitors

Indexed keywords

1 BENZYLIMIDAZOLE; ALDOSTERONE SYNTHASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CYP11B1 INHIBITOR; CYTOCHROME P450 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME INHIBITOR; EPLERENONE; ETOMIDATE; FAD 286; FADROZOLE; KETOCONAZOLE; LCI 699; METYRAPONE; MINERALOCORTICOID ANTAGONIST; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; ALDOSTERONE URINE LEVEL; ARTICLE; DRUG DESIGN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HYPERTENSION; HYPONATREMIA; LUNG FIBROBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME; POTASSIUM BLOOD LEVEL; PRIMARY HYPERALDOSTERONISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCHIZOSACCHAROMYCES POMBE; SIDE EFFECT; SODIUM EXCRETION; WEIGHT REDUCTION;

ALDOSTERONE SYNTHASE; ANIMALS; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE;

EID: 84881345238     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313120003     Document Type: Article

References (118)

1. Guengerich, F. P.; Cheng, Q. Orphans in the human cytochrome P450 superfamily: approaches to discovering functions and relevance in pharmacology. Pharmacol Rev. 2011, 63 (3), 684-99.
2. Schuster, I.; Bernhardt, R. Inhibition of cytochromes P450: existing and new promising therapeutic targets. Drug Metab Rev. 2007, 39 (2-3), 481-99.
3. Baston, E.; Leroux, F. R. Inhibitors of steroidal cytochrome P450 enzymes as targets for drug development. Recent Pat Anticancer Drug Discov. 2007, 2 (1), 31-58.
4. Bruno, R. D.; Njar, V. C. Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem. 2007, 15 (15), 5047-60.
5. Haining, R. L.; Nichols-Haining, M. Cytochrome P450-catalyzed pathways in human brain: metabolism meets pharmacology or old drugs with new mechanism of action? Pharmacol Ther. 2007, 113 (3), 537-45.
6. Nishimoto, K.; Nakagawa, K.; Li, D.; Kosaka, T.; Oya, M.; Mikami, S.; Shibata, H.; Itoh, H.; Mitani, F.; Yamazaki, T.; Ogishima, T.; Suematsu, M.; Mukai, K. Adrenocortical zonation in humans under normal and pathological conditions. J Clin Endocrinol Metab. 2010, 95 (5), 2296-305.
7. Ziegler, G. A.; Schulz, G. E. Crystal structures of adrenodoxin reductase in complex with NADP+ and NADPH suggesting a mechanism for the electron transfer of an enzyme family. Biochemistry. 2000, 39 (36), 10986-95.
8. Ewen, K. M.; Kleser, M.; Bernhardt, R. Adrenodoxin: the archetype of vertebrate-type [2Fe-2S] cluster ferredoxins. Biochim Biophys Acta 2011, 1814 (1), 111-25.
9. Payne, A. H.; Hales, D. B. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev. 2004, 25 (6), 947-70.
10. Tomaschitz, A.; Pilz, S.; Ritz, E.; Obermayer-Pietsch, B.; Pieber, T. R. Aldosterone and arterial hypertension. Nat Rev Endocrinol 2009, 6 (2), 83-93.
11. Krug, A. W.; Pojoga, L. H.; Williams, G. H.; Adler, G. K. Cell membrane-associated mineralocorticoid receptors? New evidence. Hypertension 2011, 57 (6), 1019-25.
12. Schrier, R. W.; Masoumi, A.; Elhassan, E. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol 2010, 5 (6), 1132-40.
13. Vinson, G. P.; Coghlan, J. P. Expanding view of aldosterone action, with an emphasis on rapid action. Clin Exp Pharmacol Physiol. 2010, 37 (4), 410-6.
14. Messaoudi, S.; Azibani, F.; Delcayre, C.; Jaisser, F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol. 2012, 350 (2), 266-72.
15. Briet, M.; Schiffrin, E. L. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010, 6 (5), 261-73.
16. Briet, M.; Schiffrin, E. L. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep. 2011, 13 (2), 163-72.
17. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996, 78 (8), 902-7.
18. Pitt, B.; Williams, G.; Remme, W.; Martinez, F.; Lopez-Sendon, J.; Zannad, F.; Neaton, J.; Roniker, B.; Hurley, S.; Burns, D.; Bittman, R.; Kleiman, J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001, 15 (1), 79-87.
19. Pitt, B.; Remme, W.; Zannad, F.; Neaton, J.; Martinez, F.; Roniker, B.; Bittman, R.; Hurley, S.; Kleiman, J.; Gatlin, M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003, 348 (14), 1309-21.
20. Schrier, R. W. Aldosterone 'escape' vs 'breakthrough'. Nat Rev Nephrol. 2011, 6 (2), 61.
21. Bomback, A. S.; Klemmer, P. J. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol. 2007, 3 (9), 486-92.
22. Bertocchio, J. P.; Warnock, D. G.; Jaisser, F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int 2011, 79 (10), 1051-60.
23. Bramlage, P.; Turgonyi, E.; Montalescot, G. Aldosterone blockade: current research and future trends. Eur Heart J Supp. 2011, 13 (Suppl. B), B46-B50.
24. Tamargo, J.; Lopez-Sendon, J. Novel therapeutic targets for the treatment of heart failure. Nat Rev Drug Discov 1038, 10 (7), 536-55.
25. Lu, P.; Alterman, M. A.; Chaurasia, C. S.; Bambal, R. B.; Hanzlik, R. P. Heme-coordinating analogs of lauric acid as inhibitors of fatty acid omega-hydroxylation. Arch Biochem Biophys. 1997, 337 (1), 1-7.
26. Mornet, E.; Dupont, J.; Vitek, A.; White, P. C. Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta). J Biol Chem. 1989, 264 (35), 20961-7.
27. Vukelic, S.; Stojadinovic, O.; Pastar, I.; Rabach, M.; Krzyzanowska, A.; Lebrun, E.; Davis, S. C.; Resnik, S.; Brem, H.; Tomic-Canic, M. Cortisol synthesis in epidermis is induced by IL-1 and tissue injury. J Biol Chem 2011, 286 (12), 10265-75.
28. Oelkers, W. Adrenal insufficiency. N Engl J Med. 1996, 335 (16), 1206-12.
29. Wagner, R. L.; White, P. F. Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology. 1984, 61 (6), 647-51.
30. Wagner, R. L.; White, P. F.; Kan, P. B.; Rosenthal, M. H.; Feldman, D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med. 1984, 310 (22), 1415-21.
31. Bureik, M.; Hubel, K.; Dragan, C. A.; Scher, J.; Becker, H.; Lenz, N.; Bernhardt, R. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11betahydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension. Mol Cell Endocrinol. 2004, 217 (1-2), 249-54.
32. Okamoto, M.; Nonaka, Y.; Takemori, H.; Doi, J. Molecular identity and gene expression of aldosterone synthase cytochrome P450. Biochem Biophys Res Commun. 2005, 338 (1), 325-30.
33. Mukai, K.; Imai, M.; Shimada, H.; Ishimura, Y. Isolation and characterization of rat CYP11B genes involved in late steps of mineralo-and glucocorticoid syntheses. J Biol Chem. 1993, 268 (12), 9130-7.
34. Davioud, E.; Piffeteau, A.; Delorme, C.; Coustal, S.; Marquet, A. 18-Vinyldeoxycorticosterone: a potent inhibitor of the bovine cytochrome P-450(11) beta. Bioorg Med Chem. 1998, 6 (10), 1781-8.
35. Hartmann, R. W.; Muller, U.; Ehmer, P. B. Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis. Eur J Med Chem. 2003, 38 (4), 363-6.
36. Zhou, M.; Gomez-Sanchez, C. E. Cloning and expression of a rat cytochrome P-450 11 beta-hydroxylase/aldosterone synthase (CYP11B2) cDNA variant. Biochem Biophys Res Commun. 1993, 194 (1), 112-7.
37. Zhou, M. Y.; Gomez-Sanchez, E. P.; Foecking, M. F.; Gomez-Sanchez, C. E. Cloning and expression of the rat adrenal cytochrome P-450 11B3 (CYP11B3) enzyme cDNA: preferential 18-hydroxylation over 11 beta-hydroxylation of DOC. Mol Cell Endocrinol. 1995, 114 (1-2), 137-45.
38. Kawamoto, T.; Mitsuuchi, Y.; Toda, K.; Miyahara, K.; Yokoyama, Y.; Nakao, K.; Hosoda, K.; Yamamoto, Y.; Imura, H.; Shizuta, Y. Cloning of cDNA and genomic DNA for human cytochrome P-45011 beta. FEBS Lett. 1990, 269 (2), 345-9.
39. Pelletier, G.; Li, S.; Luu-The, V.; Tremblay, Y.; Belanger, A.; Labrie, F. Immunoelectron microscopic localization of three key steroidogenic enzymes (cytochrome P450(scc), 3 betahydroxysteroid dehydrogenase and cytochrome P450(c17) in rat adrenal cortex and gonads. J Endocrinol. 2001, 171 (2), 373-83.
40. Brock, B. J.; Waterman, M. R. Biochemical differences between rat and human cytochrome P450c17 support the different steroidogenic needs of these two species. Biochemistry. 1999, 38 (5), 1598-606.
41. Ries, C.; Lucas, S.; Heim, R.; Birk, B.; Hartmann, R. W. Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo. J Steroid Biochem Mol Biol. 2009, 116 (3-5), 121-6.
42. Rigel, D. F.; Fu, F.; Beil, M.; Hu, C. W.; Liang, G.; Jeng, A. Y. Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone. J Pharmacol Exp Ther. 2010, 334 (1), 232-43.
43. Nonaka, Y.; Fujii, T.; Kagawa, N.; Waterman, M. R.; Takemori, H.; Okamoto, M. Structure/function relationship of CYP11B1 associated with Dahl's salt-resistant rats--expression of rat CYP11B1 and CYP11B2 in Escherichia coli. Eur J Biochem. 1998, 258 (2), 869-78.
44. Zollner, A.; Kagawa, N.; Waterman, M. R.; Nonaka, Y.; Takio, K.; Shiro, Y.; Hannemann, F.; Bernhardt, R. Purification and functional characterization of human 11beta hydroxylase expressed in Escherichia coli. FEBS J. 2008, 275 (4), 799-810.
45. Hobler, A.; Kagawa, N.; Hutter, M. C.; Hartmann, M. F.; Wudy, S. A.; Hannemann, F.; Bernhardt, R. Human aldosterone synthase: Recombinant expression in E. coli and purification enables a detailed biochemical analysis of the protein on the molecular level. J Steroid Biochem Mol Biol 2012, 132(1-2), 57-65.
46. Jefcoate, C. R. Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy. Methods Enzymol. 1978, 52, 258-79.
47. Yano, J. K.; Denton, T. T.; Cerny, M. A.; Zhang, X.; Johnson, E. F.; Cashman, J. R. Synthetic inhibitors of cytochrome P450 2A6: inhibitory activity, difference spectra, mechanism of inhibition, and protein cocrystallization. J Med Chem. 2006, 49 (24), 6987-7001.
48. Ford, D. K.; Yerganian, G. Observations on the chromosomes of Chinese hamster cells in tissue culture. J Natl Cancer Inst. 1958, 21 (2), 393-425.
49. Chu, E. H.; Malling, H. V. Mammalian cell genetics. II. Chemical induction of specific locus mutations in Chinese hamster cells in vitro. Proc Natl Acad Sci U S A. 1968, 61 (4), 1306-12.
50. Bradley, M. O.; Bhuyan, B.; Francis, M. C.; Langenbach, R.; Peterson, A.; Huberman, E. Mutagenesis by chemical agents in V79 chinese hamster cells: a review and analysis of the literature. A report of the Gene-Tox Program. Mutat Res. 1981, 87 (2), 81-142.
51. Platt, K. L.; Utesch, D.; Gemperlein-Mertes, I.; Glatt, H. R.; Oesch, F. Metabolizing systems in short-term in vitro tests for carcinogenicity. Food Chem Toxicol. 1986, 24 (6-7), 721-9.
52. Doehmer, J.; Dogra, S.; Friedberg, T.; Monier, S.; Adesnik, M.; Glatt, H.; Oesch, F. Stable expression of rat cytochrome P-450IIB1 cDNA in Chinese hamster cells (V79) and metabolic activation of aflatoxin B1. Proc Natl Acad Sci U S A. 1988, 85 (16), 5769-73.
53. Sugano, S.; Miura, R.; Morishima, N. Identification of intermediates in the conversion of cholesterol to pregnenolone with a reconstituted cytochrome p-450scc system: accumulation of the intermediate modulated by the adrenodoxin level. J Biochem. 1996, 120 (4), 780-7.
54. Lin, H. L.; Zhang, H.; Medower, C.; Hollenberg, P. F.; Johnson, W. W. Inactivation of cytochrome P450 (P450) 3A4 but not P450 3A5 by OSI-930, a thiophene-containing anticancer drug. Drug Metab Dispos. 2011, 39 (2), 345-50.
55. Mast, N.; Annalora, A. J.; Lodowski, D. T.; Palczewski, K.; Stout, C. D.; Pikuleva, I. A. Structural basis for three-step sequential catalysis by the cholesterol side chain cleavage enzyme CYP11A1. J Biol Chem. 2011, 286 (7), 5607-13.
56. Im, S. C.; Waskell, L. The interaction of microsomal cytochrome P450 2B4 with its redox partners, cytochrome P450 reductase and cytochrome b(5). Arch Biochem Biophys. 2011, 507 (1), 144-53.
57. Sethumadhavan, K.; Bellino, F. L. Human placental estrogen synthetase (aromatase). Effect of environment on the kinetics of protein-protein and substrate-protein interactions and the production of 19-oxygenated androgen intermediates in the purified reconstituted cytochrome P450 enzyme system. J Steroid Biochem Mol Biol. 1991, 39 (3), 381-94.
58. LaSala, D.; Shibanaka, Y.; Jeng, A. Y. Coexpression of CYP11B2 or CYP11B1 with adrenodoxin and adrenodoxin reductase for assessing the potency and selectivity of aldosterone synthase inhibitors. Anal Biochem. 2009, 394 (1), 56-61.
59. Omura, T. Mitochondrial P450s. Chem Biol Interact. 2006, 163 (1-2), 86-93.
60. Wang, T.; Rainey, W. E. Human adrenocortical carcinoma cell lines. Mol and Cell Endocrinol 2012, 351 (1), 58-65.
61. Asif, A. R.; Ljubojevic, M.; Sabolic, I.; Shnitsar, V.; Metten, M.; Anzai, N.; Muller, G. A.; Burckhardt, G.; Hagos, Y. Regulation of steroid hormone biosynthesis enzymes and organic anion transporters by forskolin and DHEA-S treatment in adrenocortical cells. Am J Physiol Endocrinol Metab. 2006, 291 (6), E1351-9.
62. Asif, A. R.; Steffgen, J.; Metten, M.; Grunewald, R. W.; Muller, G. A.; Bahn, A.; Burckhardt, G.; Hagos, Y. Presence of organic anion transporters 3 (OAT3) and 4 (OAT4) in human adrenocortical cells. Pflugers Arch. 2005, 450 (2), 88-95.
63. Bello-Reuss, E.; Ernest, S.; Holland, O. B.; Hellmich, M. R. Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Am J Physiol Cell Physiol. 2000, 278 (6), C1256-65.
64. Hille, U. E.; Zimmer, C.; Vock, C. A.; Hartmann, R. W. First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases. ACS Med Chem Lett 2011, 2 (1), 2-6.
65. Roumen, L.; Sanders, M. P. A.; Pieterse, K.; Hilbers, P. A. J.; Plate, R.; Custers, E.; Gooyer, M.; Smits, J. F. M.; Beugels, I.; Emmen, J.; Ottenheijm, H. C. J.; Leysen, D.; Hermans, J. J. R. Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics. J Comput Aided Mol Des. 2007, 21 (8), 455-471.
66. Fassnacht, M.; Hahner, S.; Beuschlein, F.; Klink, A.; Reincke, M.; Allolio, B. New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line. Eur J Clin Invest. 2000, 30 (Suppl 3), 76-82.
67. Johansson, M. K.; Sanderson, J. T.; Lund, B. O. Effects of 3-MeSO2-DDE and some CYP inhibitors on glucocorticoid steroidogenesis in the H295R human adrenocortical carcinoma cell line. Toxicol In vitro. 2002, 16 (2), 113-21.
68. Voets, M.; Antes, I.; Scherer, C.; Muller-Vieira, U.; Biemel, K.; Marchais-Oberwinkler, S.; Hartmann, R. W. Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem. 2006, 49 (7), 2222-31.
69. Hahner, S.; Sturmer, A.; Fassnacht, M.; Hartmann, R. W.; Schewe, K.; Cochran, S.; Zink, M.; Schirbel, A.; Allolio, B. Etomidate unmasks intraadrenal regulation of steroidogenesis and proliferation in adrenal cortical cell lines. Horm Metab Res. 2010, 42 (7), 528-34.
70. Zolle, I. M.; Berger, M. L.; Hammerschmidt, F.; Hahner, S.; Schirbel, A.; Peric-Simov, B. New selective inhibitors of steroid 11betahydroxylation in the adrenal cortex. Synthesis and structure-activity relationship of potent etomidate analogues. J Med Chem. 2008, 51 (7), 2244-53.
71. Cotten, J. F.; Forman, S. A.; Laha, J. K.; Cuny, G. D.; Husain, S. S.; Miller, K. W.; Nguyen, H. H.; Kelly, E. W.; Stewart, D.; Liu, A.; Raines, D. E. Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology. 2010, 112 (3), 637-44.
72. Ulmschneider, S.; Muller-Vieira, U.; Klein, C. D.; Antes, I.; Lengauer, T.; Hartmann, R. W. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005, 48 (5), 1563-75.
73. Roumen, L.; Peeters, J. W.; Emmen, J. M.; Beugels, I. P.; Custers, E. M.; de Gooyer, M.; Plate, R.; Pieterse, K.; Hilbers, P. A.; Smits, J. F.; Vekemans, J. A.; Leysen, D.; Ottenheijm, H. C.; Janssen, H. M.; Hermans, J. J. Synthesis, biological evaluation, and molecular modeling of 1-benzyl-1H-imidazoles as selective inhibitors of aldosterone synthase (CYP11B2). J Med Chem 2010, 53 (4), 1712-25.
74. Fiebeler, A.; Nussberger, J.; Shagdarsuren, E.; Rong, S.; Hilfenhaus, G.; Al-Saadi, N.; Dechend, R.; Wellner, M.; Meiners, S.; Maser-Gluth, C.; Jeng, A. Y.; Webb, R. L.; Luft, F. C.; Muller, D. N. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation. 2005, 111 (23), 3087-94.
75. Hu, Q.-Y.; Ksander, G.; Meredith, E.; Monovich, L. G.; Papillon, J.; Schumacher, C. Use of an adrenal hormone-modifying agent. 2011-US211002011088188, 20110113., 2011.
76. Ksander, G. M.; Meredith, E.; Monovich, L. G.; Papillon, J.; Firooznia, F.; Hu, Q.-Y. Preparation of condensed imidazole derivatives for the inhibition of aldosterone synthase and aromatase. 2006-US329122007024945, 20060823., 2007.
77. Raven, P. W.; Checkley, S. A.; Taylor, N. F. Extra-adrenal effects of metyrapone include inhibition of the 11-oxoreductase activity of 11 beta-hydroxysteroid dehydrogenase: a model for 11-HSD I deficiency. Clin Endocrinol (Oxf). 1995, 43 (5), 637-44.
78. Hays, S. J.; Tobes, M. C.; Gildersleeve, D. L.; Wieland, D. M.; Beierwaltes, W. H. Structure-activity relationship study of the inhibition of adrenal cortical 11 beta-hydroxylase by new metyrapone analogues. J Med Chem. 1984, 27 (1), 15-9.
79. Tobes, M. C.; Hays, S. J.; Gildersleeve, D. L.; Wieland, D. M.; Beierwaltes, W. H. Adrenal cortical 11 beta-hydroxylase and sidechain cleavage enzymes. Requirement for the A-or B-pyridyl ring in metyrapone for inhibition. J Steroid Biochem. 1985, 22 (1), 103-10.
80. Vasaitis, T. S.; Bruno, R. D.; Njar, V. C. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol. 2011, 125 (1-2), 23-31.
81. Denner, K.; Vogel, R.; Schmalix, W.; Doehmer, J.; Bernhardt, R. Cloning and stable expression of the human mitochondrial cytochrome P45011B1 cDNA in V79 Chinese hamster cells and their application for testing of potential inhibitors. Pharmacogenetics. 1995, 5 (2), 89-96.
82. Hille, U. E.; Zimmer, C.; Haupenthal, J.; Hartmann, R. W. Optimization of the First Selective Steroid-11b-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases. ACS Med Chem Lett 2011, 2 (8), 559-564.
83. Forman, S. A. Clinical and molecular pharmacology of etomidate. Anesthesiology. 2011, 114 (3), 695-707.
84. Cooper, M. S.; Stewart, P. M. Corticosteroid insufficiency in acutely ill patients. N Engl J Med. 2003, 348 (8), 727-34.
85. Cotten, J. F.; Husain, S. S.; Forman, S. A.; Miller, K. W.; Kelly, E. W.; Nguyen, H. H.; Raines, D. E. Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology. 2009, 111 (2), 240-9.
86. Pejo, E.; Cotten, J. F.; Kelly, E. W.; Le Ge, R.; Cuny, G. D.; Laha, J. K.; Liu, J.; Lin, X. J.; Raines, D. E. In vivo and In vitro Pharmacological Studies of Methoxycarbonyl-Carboetomidate. Anesth Analg 2011, 2011, 14.
87. Pejo, E.; Feng, Y.; Chao, W.; Cotten, J. F.; Le Ge, R.; Raines, D. E. Differential effects of etomidate and its pyrrole analogue carboetomidate on the adrenocortical and cytokine responses to endotoxemia. Crit Care Med. 2012, 40 (1), 187-92.
88. Bergstrom, M.; Bonasera, T. A.; Lu, L.; Bergstrom, E.; Backlin, C.; Juhlin, C.; Langstrom, B. In vitro and in vivo primate evaluation of carbon-11-etomidate and carbon-11-metomidate as potential tracers for PET imaging of the adrenal cortex and its tumors. J Nucl Med. 1998, 39 (6), 982-9.
89. Tominaga, T.; Adachi, I.; Sasaki, Y.; Tabei, T.; Ikeda, T.; Takatsuka, Y.; Toi, M.; Suwa, T.; Ohashi, Y. Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer. Ann Oncol. 2003, 14 (1), 62-70.
90. Demers, L. M.; Melby, J. C.; Wilson, T. E.; Lipton, A.; Harvey, H. A.; Santen, R. J. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. J Clin Endocrinol Metab 1990, 70 (4), 1162-6.
91. Dowsett, M.; Stein, R. C.; Mehta, A.; Coombes, R. C. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol (Oxf) 1990, 32 (5), 623-34.
92. Demers, L. M.; Lipton, A.; Harvey, H. A.; Hanagan, J.; Mulagha, M.; Santen, R. J. The effects of long term fadrozole hydrochloride treatment in patients with advanced stage breast cancer. J Steroid Biochem Mol Biol. 1993, 44 (4-6), 683-5.
93. Santen, R. J.; Demers, L. M.; Lynch, J.; Harvey, H.; Lipton, A.; Mulagha, M.; Hanagan, J.; Garber, J. E.; Henderson, I. C.; Navari, R. M.; et al., Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor. J Clin Endocrinol Metab. 1991, 73 (1), 99-106.
94. Andersen, K.; Hartman, D.; Peppard, T.; Hermann, D.; Van Ess, P.; Lefkowitz, M.; Trapani, A. The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study. J Clin Hypertens 2012, 14 (9), 580-7.
95. Belkina, N. V.; Lisurek, M.; Ivanov, A. S.; Bernhardt, R. Modelling of three-dimensional structures of cytochromes P450 11B1 and 11B2. J Inorg Biochem. 2001, 87 (4), 197-207.
96. Lucas, S.; Negri, M.; Heim, R.; Zimmer, C.; Hartmann, R. W. Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives. J Med Chem. 2011, 54 (7), 2307-19.
97. Delorme, C.; Piffeteau, A.; Sobrio, F.; Marquet, A. Mechanismbased inactivation of bovine cytochrome P-450(11beta) by 18-unsaturated progesterone derivatives. Eur J Biochem. 1997, 248 (1), 252-60.
98. Delorme, C.; Piffeteau, A.; Viger, A.; Marquet, A. Inhibition of bovine cytochrome P-450(11 beta) by 18-unsaturated progesterone derivatives. Eur J Biochem. 1995, 232 (1), 247-56.
99. Viger, A.; Coustal, S.; Perard, S.; Piffeteau, A.; Marquet, A. 18-Substituted progesterone derivatives as inhibitors of aldosterone biosynthesis. J Steroid Biochem. 1989, 33 (1), 119-24.
100. Gomez-Sanchez, C. E.; Gomez-Sanchez, E. P.; Foecking, M. F.; Zhou, M. Y. Inhibition of steroidogenesis in rat adrenal cells by 18-ethynyldeoxycorticosterone: evidence for an alternative pathway of aldosterone biosynthesis. J Steroid Biochem Mol Biol. 1997, 62 (2/3), 207-212.
101. Silverman, R. B. Mechanism-based enzyme inactivation: chemistry and enzymology 1. (1988).-210 S. CRC Press: Boca Raton, Fla., 1988.
102. Silverman, R. B. Mechanism-based enzyme inactivation: chemistry and enzymology 2. (1988).-265 S. CRC Press: Boca Raton, Fla., 1988.
103. Johnston, J. O.; Wright, C. L.; Holbert, G. W. Enzyme-activated inhibitors of steroidal hydroxylases. J Steroid Biochem Mol Biol. 1995, 52 (1), 17-34.
104. Yamakita, N.; Chiou, S.; Gomez-Sanchez, C. E. Inhibition of aldosterone biosynthesis by 18-ethynyl-deoxycorticosterone. Endocrinology. 1991, 129 (5), 2361-6.
105. Rafestin-Oblin, M. E.; Couette, B.; Barlet-Bas, C.; Cheval, L.; Viger, A.; Doucet, A. Renal action of progesterone and 18-substituted derivatives. Am J Physiol. 1991, 260 (6 Pt 2), F828-32.
106. Hartmann, R. W. Selective inhibition of steroidogenic P450 enzymes: current status and future perspectives. Eur J Pharm Sci 1994, 2 (1-2), 15-16.
107. Ulmschneider, S.; Muller-Vieira, U.; Mitrenga, M.; Hartmann, R. W.; Oberwinkler-Marchais, S.; Klein, C. D.; Bureik, M.; Bernhardt, R.; Antes, I.; Lengauer, T. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem. 2005, 48 (6), 1796-805.
108. Voets, M.; Antes, I.; Scherer, C.; Muller-Vieira, U.; Biemel, K.; Barassin, C.; Marchais-Oberwinkler, S.; Hartmann, R. W. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem. 2005, 48 (21), 6632-42.
109. Ulmschneider, S.; Negri, M.; Voets, M.; Hartmann, R. W. Development and evaluation of a pharmacophore model for inhibitors of aldosterone synthase (CYP11B2). Bioorg Med Chem Lett. 2006, 16 (1), 25-30.
110. Parke, D. V. Activation mechanisms to chemical toxicity. Arch Toxicol. 1987, 60 (1-3), 5-15.
111. Heim, R.; Lucas, S.; Grombein, C. M.; Ries, C.; Schewe, K. E.; Negri, M.; Muller-Vieira, U.; Birk, B.; Hartmann, R. W. Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity. J Med Chem. 2008, 51 (16), 5064-74.
112. Lucas, S.; Heim, R.; Negri, M.; Antes, I.; Ries, C.; Schewe, K. E.; Bisi, A.; Gobbi, S.; Hartmann, R. W. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem. 2008, 51 (19), 6138-49.
113. Lucas, S.; Heim, R.; Ries, C.; Schewe, K. E.; Birk, B.; Hartmann, R. W. In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives. J Med Chem. 2008, 51 (24), 8077-87.
114. Zimmer, C.; Hafner, M.; Zender, M.; Ammann, D.; Hartmann, R. W.; Vock, C. A. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2). Bioorg Med Chem Lett. 2010, 21 (1), 186-90.
115. Adams, C. M.; Hu, C. W.; Jeng, A. Y.; Karki, R.; Ksander, G.; Lasala, D.; Leung-Chu, J.; Liang, G.; Liu, Q.; Meredith, E.; Rao, C.; Rigel, D. F.; Shi, J.; Smith, S.; Springer, C.; Zhang, C. The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase. Bioorg Med Chem Lett. 2010, 20 (15), 4324-7.
116. Godefroi, E. F.; Janssen, P. A.; Vandereycken, C. A.; Vanheertum, A. H.; Niemegeers, C. J. DL-1-(1-Arylalkyl)imidazole-5-carboxylate esters. A novel type of hypnotic agents. J Med Chem. 1965, 8, 220-3.
117. Menard, J.; Watson, C.; Rebello, S.; Zhang, Y. M.; Dole, W. P. Hormonal and electrolyte responses to the aldosterone synthase inhibitor LCI699 in sodium depleted healthy subjects. J Am Coll Cardiol 2010, 55 (10), A61. E583.
118. Amar, L.; Azizi, M.; Menard, J.; Peyrard, S.; Watson, C.; Plouin, P. F. Aldosterone synthase inhibition with LCI699: a proof-ofconcept study in patients with primary aldosteronism. Hypertension. 2010, 56 (5), 831-8.